TriBiotica’s Haplomer™ technology platform aims to exploit the power of immunotherapy in a vast array of cancer types.

Cancer immunotherapy is revolutionizing medicine, producing extraordinary results in patients with select types of tumors.  To bring these treatments to a much wider population of patients, Haplomers harness tumor-specific gene signatures to enable more effective targeted immunotherapy.  Haplomers are unique building blocks that are assembled within cancer cells to create an active therapeutic without harming healthy cells.  Our approach couples the proven effectiveness of immunotherapy with the precise targeting of genetic medicine.